SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 52.40-1.5%Dec 31 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biotech Jim who wrote (25902)2/19/2008 10:51:10 AM
From: Biomaven  Read Replies (4) of 52153
 
Thanks Jim.

I assume it's simply a nomenclature coincidence that CCR2 appears to have a role in MS? I can't keep all the overlapping chemokine functionality straight.

BTW, have you looked at the INCY CCR2 program at all?

On CXCR2, Pharmacopeia has some sort of antagonist partnered by SGP in phase II for COPD. GSK has some sort of program too, but I don't know anything about it.

There's a company ChemoCentryx that recently filed for an IPO that seems to be focused on the chemokine space. Heard anything about them at all?

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News